Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors and CKD: Are You a #Flozinator?

Sodium/glucose cotransporter 2 (SGLT2) inhibitors have rapidly emerged as a novel therapy to reduce the rate of progression of chronic kidney disease (CKD). With humble beginnings in the 19th century for treating malaria, this class of drugs initially developed for the treatment of diabetes has now...

Descripción completa

Detalles Bibliográficos
Autores principales: Krishnan, Anoushka, Shankar, Mythri, Lerma, Edgar V., Wiegley, Nasim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
GlomCon Mini Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10006698/
https://www.ncbi.nlm.nih.gov/pubmed/36915368
http://dx.doi.org/10.1016/j.xkme.2023.100608

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10006698/
https://www.ncbi.nlm.nih.gov/pubmed/36915368
http://dx.doi.org/10.1016/j.xkme.2023.100608

Ejemplares similares